In the Comparative Effects of Low and High Doses of the Angiotensin‐Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure (ATLAS) trial (N = 3164), comparing between high‐ and low‐dose groups, relatively small difference in mean SBP (<5 mmHg) and similar incidence rate of major increases in creatinine (>1 mg/dl) were observed.3 This evidence concerns the gene ACE and congestive heart failure.